MIT and Scripps scientists explore a single-dose vaccine approach by combining two immune-boosting ingredients.

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

When it comes to vaccines, where they go into your body can make a surprising difference in how well they work. Scientists in Sydney have uncovered how getting a booster shot in the same arm as your ...

Researchers at Massachusetts Institute of Technology (MIT) have developed a way to 'supercharge' vaccines to the extent that ...

A panelist discusses recent advancements in bispecific antibody therapies for relapsed/refractory multiple myeloma, ...

Hidden food sensitivities cause delayed immune reactions that escape allergy tests but trigger chronic inflammation and ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

The protein language model is trained solely on paired human antibody sequences with scalable applications in antibody ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma patients, including a 100% response in those naïve to B-cell maturation ...

Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...